A year ago, Roy Prop alerted us all to the clinical trial of Voyager Therapeutics.
Instead of kicking a dying horse, the Substantia Nigra, Voyager had the daring, clever idea of working with a nearby brain region, the Putamen, which is not Dopamine-challenged. By drilling a hole through the skull and injecting fresh genes, they hope to stimulate more production of Dopamine. Well, before you smirk, shake your head, and call this just another of countless Parkinson's Pipe Dreams, listen up.
The phase 1b trial, involving 15 patients with advanced PD has been completed. And the news is all good:
With this strong success under their belts, Phase 2/3 trials may begin as soon as next year. Let's keep posted.